Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of TL-895 in Myelofibrosis Patients Not Suitable for Janus Kinase Inhibitors
2020-002393-27Phase 2Active
- Sponsor
- Telios Pharma
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TL-895 in myelofibrosis (MF) (3 cohorts), sponsored by Telios Pharma. Primary endpoint: Recommended Phase 2 Dose (RP2D) and Schedule Determination. Started Nov 2020; status: active.
02
Drugs
TL-895
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-002393-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002393-27.